← Amneal Pharmaceuticals, Inc. Class A Common Stock overview

Amneal Pharmaceuticals, Inc. Class A Common Stock vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

Q3 2026
▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

  • Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.

    This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.

  • Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.

    The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.

  • FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.

    New regulatory approval directly enables additional sales and market share in an existing product category.

  • Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.

    This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

August 2026
▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

  • Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.

    This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.

  • Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.

    The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.

  • FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.

    New regulatory approval directly enables additional sales and market share in an existing product category.

  • Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.

    This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

Latest
▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

  • Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.

    This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.

  • Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.

    The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.

  • FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.

    New regulatory approval directly enables additional sales and market share in an existing product category.

  • Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.

    This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.